Although Yupingfeng's clinical impact on asthmatics has been established, no research has been done to substantiate its pharmacological mechanism. Hypothesis purpose to understand YPF's possible pharmacological mechanism and molecular basis for use in the treatment of asthma. Study methodology and design: Initially, a systems pharmacology-based approach was employed to systematically elucidate the mechanism of YPF in asthma by integrating pharmacokinetic screening, target prediction, network analysis, GO, and KEGG analyses. Second, using the online programme GEO2R, differentially expressed genes between asthma sufferers and healthy controls were discovered. Finally, molecular docking was carried out using the Discovery Studio 2020 Client version to find the ability of compounds to attach to targets based on systems pharmacology and DEGs data. The C57BL/6 mice that had been exposed to ovalbumin received either YPF or its efficient compound to evaluate the forecasts. After target fishing and matching, a total of 35 active compounds were eliminated, leaving 87 prospective targets for additional investigation. The primary components of YPF were determined to be quercetin, kaempferol, and wogonin. The top signalling pathways in KEGG enrichment were found to be phosphatidylinositol 3-kinase protein kinase tumour necrosis factor and IL-17.
Share this article